Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD and T2D.

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

The results of the clinical trial show that Semaglutide improved quality of life and increased the distance that participants ...

The STRIDE trial showed that symptomatic PAD patients with type 2 diabetes treated with semaglutide 1mg for a year experienced substantial functional benefits related to their PAD compared to the ...